Time to first treatment with biologic agents for ulcerative colitis and Crohn's disease across four Nordic countries: Results from the TRINordic study

被引：0
|
作者：
Hoivik, M. [1 ]
Lordal, M. [2 ]
Burisch, J. [3 ]
Langholz, E. [4 ]
Knudsen, T. [5 ]
Voutilainen, M. [6 ]
Moum, B. [1 ]
Anisdahl, K. [1 ]
Saebo, B. [7 ]
Haiko, P. [8 ]
Malmgren, C. [9 ]
Coskun, M. [10 ]
Melberg, H. O. [11 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Danderyd Hosp, Dept Gastroenterol & Hepatol, Stockholm, Sweden
[3] Hvidovre Univ Hosp, Dept Gastrounit Med Div, Hvidovre, Denmark
[4] Herlev Hosp, Dept Med Gastroenterol, Herlev, Denmark
[5] Univ Southern Denmark, Hosp South West Denmark, Dept Reg Hlth Res, Dept Med, Odense, Denmark
[6] Univ Turku, Dept Gastroenterol, Turku, Finland
[7] Takeda AS, Med Affairs, Asker, Norway
[8] Takeda Oy, Med Affairs, Helsinki, Finland
[9] Takeda Pharma AB, Dept Med Affairs, Stockholm, Sweden
[10] Dept Med Affairs, Taastrup, Denmark
[11] Univ Oslo, Inst Hlth & Soc, Dept Hlth Management & Hlth Econ, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP21
引用
收藏
页码：S060 / S061
页数：2
相关论文
共 50 条
  • [1] Annual incidence and prevalence of ulcerative colitis and Crohn's disease from 2010 to 2017 in four Nordic countries: Results from the TRINordic study
    Lordal, M.
    Burisch, J.
    Langholz, E.
    Knudsen, T.
    Voutilainen, M.
    Moum, B.
    Saebo, B.
    Paula, H.
    Malmgren, C.
    Coskun, M.
    Melberg, H. O.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S261 - S262
  • [2] Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease
    O’Toole A.
    Moss A.C.
    Current Gastroenterology Reports, 2015, 17 (8)
  • [3] Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
    Ooi, Choon Jin
    Hilmi, Ida
    Banerjee, Rupa
    Chuah, Sai Wei
    Ng, Siew Chien
    Wei, Shu Chen
    Makharia, Govind K.
    Pisespongsa, Pises
    Chen, Min Hu
    Ran, Zhi Hua
    Ye, Byong Duk
    Park, Dong Il
    Ling, Khoon Lin
    Ong, David
    Ahuja, Vineet
    Goh, Khean Lee
    Sollano, Jose
    Lim, Wee Chian
    Leung, Wai Keung
    Ali, Raja Affendi Raja
    Wu, Deng Chyang
    Ong, Evan
    Mustaffa, Nazri
    Limsrivilai, Julajak
    Hisamatsu, Tadakazu
    Yang, Suk Kyun
    Ouyang, Qin
    Geary, Richard
    De Silva, Janaka H.
    Rerknimitr, Rungsun
    Simadibrata, Marcellus
    Abdullah, Murdani
    Leong, Rupert W. L.
    INTESTINAL RESEARCH, 2019, 17 (03) : 285 - 310
  • [4] Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
    Ooi, Choon Jin
    Hilmi, Ida
    Banerjee, Rupa
    Chuah, Sai Wei
    Ng, Siew Chien
    Wei, Shu Chen
    Makharia, Govind K.
    Pisespongsa, Pises
    Chen, Min Hu
    Ran, Zhi Hua
    Ye, Byong Duk
    Park, Dong Il
    Ling, Khoon Lin
    Ong, David
    Ahuja, Vineet
    Goh, Khean Lee
    Sollano, Jose
    Lim, Wee Chian
    Leung, Wai Keung
    Ali, Raja Affendi Raja
    Wu, Deng Chyang
    Ong, Evan
    Mustaffa, Nazri
    Limsrivilai, Julajak
    Hisamatsu, Tadakazu
    Yang, Suk Kyun
    Ouyang, Qin
    Geary, Richard
    De Silva, Janaka H.
    Rerknimitr, Rungsun
    Simadibrata, Marcellus
    Abdullah, Murdani
    Leong, Rupert W. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (08) : 1296 - 1315
  • [5] Significant Variation in Biologic Use Across the United States for Crohn's Disease and Ulcerative Colitis
    Siegel, Corey A.
    Yang, Fei
    Cai, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S388 - S388
  • [6] Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
    Siegel, Corey A.
    Yang, Fei
    Eslava, Sergio
    Cai, Zhaohui
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11 : e00128
  • [7] Time trends of mortality from Crohn's disease and ulcerative colitis
    Sonnenberg, Amnon
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2007, 36 (04) : 890 - 899
  • [8] Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Yarur, A.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Mantzaris, G. J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S381 - S382
  • [9] CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Bressler, Brian
    Yarur, Andres J.
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2020, 158 (06) : S407 - S407
  • [10] Treatment outcomes of inflammatory bowel disease in the biological era-a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
    Zhao, M.
    Lordal, M.
    Langholz, E.
    Knudsen, T.
    Voutilainen, M.
    Hoivik, M. L.
    Moum, B.
    Saebo, B.
    Haiko, P.
    Malmgren, C.
    Coskun, M.
    Melberg, H. O.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S036 - S037
12345